ABSTRACT
Fibromyalgia is an increasingly prevalent condition resulting in high morbidity and economic burden for sufferers. Minimal to modest benefit has been achieved by pharmacotherapies, creating a strong rationale for novel therapies. Substantial evidence has implicated the endocannabinoid system in the modulation of fibromyalgia symptoms. However, the therapeutic potential and potential adverse effects of cannabis-based therapy in fibromyalgia are still under-reported, leading to clinicians’ hesitation to opt for such therapy. This systematic review examined the literature and provided a critical review of the safety and efficacy of cannabis-based therapy in fibromyalgia. It resulted that medical cannabis is a safe and effective treatment option for fibromyalgia, whilst further research in this area is needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by MaltaEnterprise.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data was openly available prior to initiating the study, and can be found using the DOI links below: 1. 10.3390/jcm8060807 2.https://pubmed.ncbi.nlm.nih.gov/32116208/ 3.https://pubmed.ncbi.nlm.nih.gov/30585986/ 4.https://pubmed.ncbi.nlm.nih.gov/17974490/ 5.https://pubmed.ncbi.nlm.nih.gov/20007734/#:~:text=Conclusions%3A%20Nabilone%20is%20effective%20in,to%20characterize%20long%2Dterm%20safety. 6.https://pubmed.ncbi.nlm.nih.gov/21533029/ 7.https://pubmed.ncbi.nlm.nih.gov/30418116/ 8.https://pubmed.ncbi.nlm.nih.gov/33118602/ 9.https://pubmed.ncbi.nlm.nih.gov/29461346/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
